Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Friday, February 21, 2025 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference scheduled for March 4, 2025. The presentation will be accessible via live webcast and will include a replay option afterward. Madrigal focuses on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its leading therapeutic candidate, Rezdiffra, aimed at addressing this liver disease.
Market Sentiment Analysis
POSITIVE FACTORS
Madrigal Pharmaceuticals will showcase its commitment at a major healthcare conference.
The company's product, Rezdiffra, targets a significant unmet need in liver disease.
The presentation offers an opportunity for investor engagement and visibility.
Full Press Release Details
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.